Primary chondrosarcoma of bone: a clinicopathological and oncological outcome analysis

Authors

  • S. Subbiah Department of Surgical Oncology, Government Royapettah Hospital, Kilpauk Medical College, Chennai, Tamil Nadu, India https://orcid.org/0000-0001-5289-3953
  • Priya D. Department of Surgical Oncology, Government Royapettah Hospital, Kilpauk Medical College, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20241706

Keywords:

Chondrosarcoma, Mesenchymal, Conventional chondrosarcoma, Survival

Abstract

Chondrosarcomas are a heterogenous group of cartilaginous matrix-producing malignant neoplasms. They have varied morphological features and different clinical behaviors. The tumors usually range from benign low-grade tumors or intermediate atypical cartilaginous tumors (ACTs), to malignant, aggressive high-grade tumors. A multidisciplinary team at a tertiary sarcoma centre allows for optimal management of these patients. To determine the clinicopathological and survival outcomes of patients of chondrosarcoma, we report a total of 20 cases in the last 10 years at our institution. Our results have shown that chondrosarcomas occurred in different age groups and most common location was in axial skeleton. Most common histological type was conventional chondrosarcoma and majority were high grade tumors. All patients had undergone surgery and majority of the patients were alive after many years of treatment with an overall survival of 85%. Long term survival of patients is attributed to completeness of surgical resection.

 

References

Hartley AL, Blair V, Harris M, Birch JM, Banerjee SS, Freemont AJ, et al. Sarcomas in north west England: II. Incidence. Br J Cancer. 1991;64(6):1145-50.

Andreou D, Ruppin S, Fehlberg S, Pink D, Werner M, Tunn PU. Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up. Acta Orthop. 2011;82(6):749-55.

Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop Related Res. 2007;459:40-7.

Wang Z, Chen G, Chen X, Huang X, Liu M, Pan W, et al. Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis. J Cancer. 2019;10(11):2457-63.

Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320-9.

Andreou D, Ruppin S, Fehlberg S, Pink D, Werner M, Tunn PU. Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up. Acta Orthop. 2011;82(6):749-55.

Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019;38(42):6835-49.

Heymann MF, Schiavone K, Heymann D. Bone sarcomas in the immunotherapy era. Br J Pharmacol. 2021;178(9):1955-72.

Thorkildsen J, Taksdal I, Bjerkehagen B, Haugland HK, Børge Johannesen T, Viset T, et al. Chondrosarcoma in Norway 1990-2013; an epidemiological and prognostic observational study of a complete national cohort. Acta Oncol. 2019;58(3):273-82.

Nazeri E, Gouran Savadkoohi M, Majidzadeh-A K, Esmaeili R. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. Crit Rev Oncol Hematol. 2018;131:102-9.

Lohberger B, Glaenzer D, Eck N, Steinecker-Frohnwieser B, Leithner A, Rinner B, et al. Effects of a combined therapy of bortezomib and ionizing radiation on chondrosarcoma three-dimensional spheroid cultures. Oncol Lett. 2021;21(6):428.

Wang Z, Chen G, Chen X, Huang X, Liu M, Pan W, et al. Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis. J Cancer. 2019;10(11):2457-63.

Weinschenk RC, Wang WL, Lewis VO. Chondrosarcoma. J Am Acad Orthop Surg. 2021;29(13):553-62.

Wu X, Wang Y, Sun W, Tan M. Prognostic factors and a nomogram predicting overall survival in patients with limb chondrosarcomas: a population-based study. BioMed Res Int. 2021;4510423.

Cranmer LD, Chau B, Mantilla JG, Loggers ET, Pollack SM, Kim TS, et al. Is chemotherapy associated with improved overall survival in patients with dedifferentiated chondrosarcoma? A SEER database analysis. Clin Orthop Relat Res. 2022;480(4):748-58.

Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320-9.

Downloads

Published

2024-06-26